Loading
Life sciences · Journal article
Frontiers in Oncology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose Soft tissue sarcoma (STS) is a rare but aggressive mesenchymal malignancy that accounts for less than 1% of all adult cancers. Head and neck soft tissue sarcomas (HNSTS) are infrequent malignant tumors arising from mesenchymal and neuroectodermal tissues in the head and neck region with a poor prognosis, and recurrence is predominantly local. There are few targeted management guidelines. Case description We report the case of a 77-year-old woman with postoperative recurrence of HNSTS. The patient was diagnosed with high-grade soft tissue sarcoma of the scalp in February 2025 and treated with surgery. In June 2025, the patient was diagnosed with recurrence, and was subsequently treated with combination therapy consisting of the anti-angiogenic inhibitor anlotinib and radiotherapy. In December 2025, after nine cycles, the patient showed a complete response (CR) to therapy. Conclusion This indicates that radiotherapy combined with anti-angiogenic targeted therapy may produce synergistic effects in patients with HNSTS and provide directions for future clinical decision-making.